The global landscape for DNA repair therapeutics is evolving rapidly as pharmaceutical companies intensify research efforts in precision oncology and targeted medicine. Rising cancer prevalence, increasing investments in genomic medicine, and advancements in biomarker-driven therapies are contributing to strong industry expansion across developed and emerging economies. Growing awareness...